###
中国临床研究英文版:2026,39(10):1482-1487
本文二维码信息
码上扫一扫!
罕见驱动基因阳性非小细胞肺癌脑转移治疗进展
(南京医科大学附属肿瘤医院江苏省肿瘤防治研究所江苏省肿瘤医院肿瘤内科,江苏 南京 210009)
Advances in the treatment of brain metastases in non-small cell lung cancer with rare driver-gene alterations
(Department of Medical Oncology,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,The Affiliated CancerHospital of Nanjing Medical University,Nanjing,Jiangsu 210009,China)
摘要
本文已被:浏览 216次   下载 152次
Received:February 07, 2026   Published Online:October 23, 2026
中文摘要: 随着非小细胞肺癌(NSCLC)分子分型及靶向治疗的发展,罕见驱动基因阳性NSCLC 的中枢神经系统(CNS)受累及其治疗日益受到关注。新一代小分子抑制剂和抗体偶联药物(ADCs)的发展改善了部分患者的颅内疾病控制,但不同驱动基因间的颅内治疗证据仍存在明显差异,且CNS特异性终点数据有限。靶向治疗与立体定向放射外科(SRS)等局部治疗的合理整合及多学科团队(MDT)综合管理是当前重要的治疗策略。本文综述罕见驱动基因阳性NSCLC脑转移的临床及分子特征、系统治疗进展与综合治疗策略。
Abstract:With advances in molecular profiling and targeted therapies for non-small cell lung cancer(NSCLC),central nervous system(CNS)involvement and its management in patients with rare driver-gene alterations have received increasing attention. The development of next-generation small-molecule inhibitors and antibody-drug conjugates(ADCs)has improved intracranial disease control in some patients;however,the level of evidence for intracranial treatment varies substantially across different driver alterations,and data on CNS-specific endpoints remain limited. The rational integration of targeted therapies with local treatments,such as stereotactic radiosurgery(SRS),together with multidisciplinary team(MDT)integrated management,has become an important therapeutic strategy. This review summarizes the clinical and molecular characteristics of brain metastases in NSCLC harboring rare driver-gene alterations,with a focus on advances in systemic therapies and multidisciplinary treatment strategies.
文章编号:     中图分类号:R734.2    文献标志码:A
基金项目:江苏省卫生健康委科研课题(H2023123);江苏省肿瘤医院移山计划重点项目 (YSZD202409)
引用文本:


Scan with WeChat

Scan with WeChat